Inserm Transfert, your partner for value creation and technology transfer

Inserm Transfert, founded in 2000, is the private subsidiary of Inserm, specialized in life sciences technology transfer and collaborative research projects funding. It works under a Public service Delegation Agreement (DSP).

0

patent families*

0

number of contracts and licenses*

* For the year 2019

0

millions of euros invested in Proof of concept

0

projects detected*

Serving research

The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological research to clinical development, with the aim of creating economic and societal value.

Are you a Researcher?

Protecting my results
Involving companies
Funding my project
Thinking about entrepreneurship

Are you a Company?

A response dedicated to your needs
Our strategic areas of innovation
An exceptional offer

Are you an Investor?

Investors

News

Une évaluation externe confirme le haut niveau de professionnalisme

Inserm Transfert December 2020

Le Canceropôle Provence-Alpes-Côte d’Azur et Inserm Transfert

Institutional Partnerships December 2020

CHEF DE PROJETS (H/F) – EMD_CDP_112020

Carreers

JURISTE (H/F) – JUR_JUREXP_202011

Carreers

Le consortium PBS, conduit par l’incubateur Paris Biotech

Institutional Partnerships December 2020

Inserm Transfert partenaire de la 8ème édition du congres #8AIS2020

Event November 2020

Lancement d’Atlas : Un ambitieux programme de recherche

Industrial Partnerships September 2020

Inserm Transfert renforce sa gouvernance avec notamment l’arrivée

Inserm Transfert September 2020

Inserm Transfert présente ses résultats 2019

Inserm Transfert June 2020

Inserm Transfert accompagne 7 nouveaux projets européens

Collaborative projects March 2020

4ème édition du Tech Tour Transfer Invest

Entrepreneurship February 2020

5 start-up issues de la valorisation de la recherche de l’Inserm

Entrepreneurship February 2020

Inserm Transfert sur BioFit 2019

Industrial Partnerships December 2019

Inserm Transfert et PULSALYS signent un accord de partenariat

Institutional Partnerships October 2019

Projets européens : les nouveaux succès remarquables de 2018

Collaborative projects September 2019

Inserm Transfert se félicite du Prix de l’inventeur européen

Intellectual Property July 2019

Therachon : un bel exemple de succès collectif pour une start-up,

Industrial Partnerships June 2019

Human Health Startup Factory (HHSF) le consortium porté par Inserm

Industrial Partnerships January 2019
26 Jan 2021

Vive l'#innovation qui gagne! Félicitations à @JeromeGalon d'@HalioDx, pour le prix #Jeantet-Collen en… https://t.co/gBr9Rf4M8O

26 Jan 2021

RT @HalioDx: Félicitation à @JeromeGalon, pour son prix #Jeantet-Collen en #medecinetranslationnelle pour ses travaux sur la #réponsesimmun…

22 Jan 2021

Comment faire avancer l'#innovation ? Retrouvez l'intervention de Pascale Augé, Présidente du Directoire d'… https://t.co/wCZkS5EFFR

04 Jan 2021

Toute l'équipe d'@InsermTransfert vous souhaite une bonne et belle Année 2021 pour vous, pour la #recherche, pour l… https://t.co/LSXAmUKLx6

24 Dec 2020

Toute l'équipe d'@InsermTransfert vous souhaite un très Joyeux Noël et de bonnes fêtes en famille ! https://t.co/goVE09OIzw

21 Dec 2020

@InsermTransfert est ravie d’avoir accompagné Louise Biquard, chercheuse doctorante au CRI, pour le prix de la Fond… https://t.co/tMdrgcYMPx

16 Dec 2020

20 Millions d'€ de levés : Félicitations à #Innoskel, à Elvire Gouze et à son équipe pour cette bonne nouvelle ! En… https://t.co/fZi72mxzfG

15 Dec 2020

#valorisation de la #recherche, #techtransfert, #expertise, pertinence du modèle économique, gestion de la #PI, sui… https://t.co/49aobFKY6B

15 Dec 2020

Le Canceropôle Provence-Alpes-Côte d'Azur et Inserm Transfert renforcent leur collaboration dans le domaine de la c… https://t.co/Gh67k6W1Es

14 Dec 2020

RT @Inserm: Notre dernier Canal Détox fait le point sur les #vaccins à ARN et sur leur développement au cours de cette année de pandémie de…

11 Dec 2020

Pendant le confinement, nous, on continue ! @InsermTransfert organise sa 4ème session 2020 en format digital des R… https://t.co/Je3JCiYwyI

10 Dec 2020

@InsermTransfert et le @CanceropolePACA ont le plaisir d'annoncer la signature d’un accord de partenariat pour ren… https://t.co/JH3KpDPvpH

10 Dec 2020

RT @HalioDx: 🌍🏆‍👏 Congratulations to @JeromeGalon the European Inventor 2019 Laureate for #Immunoscore. Today in the top 1% of the most inf…

09 Dec 2020

Félicitations à Nathalie Vergnolle, Directrice de recherche à l’@Inserm, Institut de recherche en santé digestive,… https://t.co/lkpd5X1v5d

08 Dec 2020

Félicitation aux lauréats des prix @Inserm 2020 Grand Prix: @DgCostagliola Prix #Recherche: Florence Ader et Franc… https://t.co/DWOFeUBCq2

08 Dec 2020

Prix @Inserm 2020 : Félicitations à @yazdanpanah_y , Prix OPECST-Inserm pour la #valorisation de la #recherche et l… https://t.co/8DxuXaGUsq

07 Dec 2020

Mardi 11h00, venez découvrir qui sont les chercheurs distingués par les prix @Inserm 2020 ! RdV sur… https://t.co/l5wq6SeEZj

04 Dec 2020

Le consortium #PBS, conduit par @ParisBiotech, avec @InsermTransfert, Université De Paris, @APHP, @Resah_fr et SHAP… https://t.co/HrY4hECbjE

30 Nov 2020

@InsermTransfert adresse ses félicitations aux 5 chercheurs @Inserm, lauréats des @SanofiFR #Awards ainsi qu’à tous… https://t.co/m3sGj5KDl9

20 Nov 2020

@congress_ais Nicolas Crouvezier, Responsable Propriété Intellectuelle @InsermTransfert, intervient le 23/11 à 16h0… https://t.co/QaOVfmahXz

Collaborative projects

High-quality support for excellent research.

EHVA

H2020

 the European HIV Vaccine Alliance (EHVA) program will develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. ...

EJP-RD

H2020

The European Joint Program on Rare Diseases brings over 130 institutions from 35 countries 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, ...

REMEDIA

H2020

The overall objective of the REMEDIA project is to determine how and to what extent the exposome affects the severity and morbidity of Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis ...

CARDIATEAM

IMI

Diabetic patients are 2.5 times more likely to develop heart failure than people without diabetes. In many patients, the diabetes causes a type of heart dysfunction called cardiomyopathy, which is ...

ENSAT-HT

H2020

This project will develop and evaluate an omics-based stratified health promotion program for patients with endocrine forms of hypertension. ...

COSY

RHU

The aim of our project is to transform the outcome and the medical care of patients with overgrowth syndromes (OS) ...

EU-TRAIN

H2020

"End stage renal diseases affect more than 3,900,000 patients worldwide with approximately 6% growth rate in 2016. Kidney transplantation is currently the best therapeutic option with around ...

KTD INNOV

RHU

"KTD-Innov combines molecular medicine (MM) and health information technology (HIT) to deliver a precision immune monitoring and diagnosis system applied in kidney transplantation: the Integrative ...

HUGODECA

H2020

"The HUGODECA project is a European funded research initiative investigating how human gonads (either an ovary or a testis) develop in the embryo in order to understand how the initially bipotential ...

CARMMA

RHU

CARMMA is based on the hypothesis that obesity co-morbidities are associated with an early senescence of adipose tissue (AT). The main objective of CARMMA is to determine the common and central ...

iVASC

RHU

iVASC est un consortium de chercheurs, de cliniciens et d’industriels, qui vise à mettre au point de nouveaux outils de recherche dans le domaine de l’athérothrombose et à les appliquer à ...

CARE

IMI

The CARE consortium is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organizations whose main objectives are the development of therapeutics (i) to provide ...

TheraLymph

H2020

Lymphedema is a disabling condition of localised accumulation of fluid in a tissue caused by a compromised lymphatic system. It is an incurable disease that affects millions of people worldwide and is...

AB-DiRecT

IMI

Developing antibacterials for resistant infections. An alarming rise globally in antibiotic-resistant infections and a search for new solutions is the motivational force behind project AB-DiRecT. The ...

IP-CURE-B

H2020

To develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune ...

VHFMoDRAD

IMI

VHFMoDRAD will develop and deliver rapid and point-of-care singel/multiplex diagnostic tool(s) that will significantly increase our capacity to handle outbreaks with Filoviruses and other viral ...

CCHFVaccine

H2020

The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) ...

ERINHA-Advance

H2020

One of the great challenges of the 21st century is to develop the capacity to prevent and react to outbreaks caused by highly pathogenic human and animal microorganisms, which are generally ...

EU-JAV

EU health programme

EU-JAV brings together the European Commission, health ministries, international policymakers and organisations, institutes, universities from 20 countries and a wide range of stakeholders, including ...

ZIKAlliance

H2020

ZIKAlliance is a multinational, multi-disciplinary research consortium comprised of 54 partners worldwide. It investigates clinical, fundamental, environmental and social aspects of ZIKV infection, in...

EBOVAC2

IMI

" The main objective of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine....

R-LINK

H2020

The main objective of this study is to identify the eligibility criteria for treatment with lithium in bipolar I disorders (BDI) in terms of response, safety and tolerability. R-LiNK proposes a ...

QUID NASH

RHU

The main aim of the QUID-NASH program is to develop a virtual liver biopsy (non invasive) for the diagnosis and staging of NASH (Non Alcoholic SteatoHepatitis) in patients with type 2 diabetes,...

PREVAC-UP

The project PREVAC-UP is built around the PREVAC consortium. Its two primary objectives are to determine (i) the long-term immunogenicity and safety and (ii) durability of humoral and cellular immune ...

PREMSTEM

H2020

PREMSTEM aims to validate umbilical cord derived human mesenchymal stem cells as a regenerative therapy for encephalopathy of prematurity to improve the quality of life for preterm infants and reduce ...

OBERON

H2020

The OBERON project will build an integrated approach for testing and assessment (IATA) to detect endocrine disruptors-related metabolic disorders by developing, improving and validating a battery of ...

MIROCALS

H2020

Efficacy and safety of low-dose IL2 (ld-IL2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients...

miniNO

H2020

The miniNO project will conduct out pioneering research on the connection between alterations in minipuberty and infantile nitric oxide (NO) signaling in the brain, and comorbidities that appear later...

MEDIT-AGEING

H2020

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all related...

MAD-CoV 2

IMI

The overall aim of MAD-CoV 2 project is to develop and deliver a treatment for COVID-19 patients, which will significantly increase our capacity to handle the current outbreak of SARS-CoV-2. In ...

JPsustaiND

H2020

The overall aim of JPsustaiND is to support the development and extension of the capacities of the EU Joint Programming Initiative on Neurodegenerative Diseases, in particular Alzheimer's (JPND). ...

JPcofuND2

H2020

With the objective of promoting research aimed at changing the trajectory of these debilitating diseases, JPco-fuND 2 launched in January 2019, a joint transnational call supported by 27 countries for...

JPco-fuND

H2020

This initiative launched a joint transnational call for proposals, as a joint effort of 20 countries, aimed at supporting international research collaborations in three JPND priority areas: ...

HERA

H2020

HERA will set the priorities for an environment and health research agenda in the EU by adopting a holistic and systemic approach in the face of global environmental changes. Research will support ...

HBM4EU

H2020

HBM4EU is a joint effort of 30 countries, the European Environment Agency and the European Commission, co-funded under Horizon 2020. The initiative is coordinating and advancing human biomonitoring in...

FAIR-PARK-II

H2020

"FAIR PARK II will primarily investigate the effects of an iron chelation therapy on the progression of handicap in Parkinson's disease. The project will run for five years (2015 - 2020) and will ...

FAIR

H2020

The project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome antimicrobial resistance in pneumonia. The research focuses on the unique immunomodulator flagellin that ...

EBRA

H2020

EBRA aims at reducing the fragmentation and duplication of research efforts and at fostering synergies through enhanced coordination of brain research efforts at the EU and global level....